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Abstract
Background: Plasma fatty acids (FAs) and micronutrients have been associated with central obesity in adults; however,
previous studies of these associations in adults have yielded mixed results. In addition, no comparable research has been
conducted among youth with type 1 diabetes (T1D).
Objective: We investigated the cross-sectional and longitudinal associations between plasma nutrient biomarkers and
waist-to-height ratio (WHtR) in youth with T1D.
Methods: These analyses included 1324 youth aged 3–20 y at T1D diagnosis with a baseline visit in the SEARCH (Search
for Diabetes in Youth) Study and a subset of 1178 of these youth with a follow-up visit an average of 23 mo (range: 16–40
mo) after their baseline visit. Plasma phospholipid FAs and vitamins were measured, and estimated desaturase activities
were calculated at baseline. Anthropometric measurements and diabetes-related assessments were collected at each
visit. Multiple linear regression was used to examine the association between plasma nutrient biomarkers and WHtR.
Results: In cross-sectional analysis, plasma palmitic acid (P = 0.004), dihomo-g-linolenic acid (DGLA; P = 0.017) and D6
desaturase (D6D; P = 0.006) were positively correlated with WHtR after adjustment of confounders. Oleic acid (OA; P =
0.002), linoleic acid (LA; P = 0.015), D9 desaturase 18 (D9D-18; P = 0.027), and vitamin D (P < 0.0001) were negatively
correlated with WHtR after adjustment. Weight status was an effect modifier (P < 0.05). In normal-weight youth, vitamin D
(P = 0.003) was negatively associated with WHtR. In obese youth, stearic acid (P = 0.037), DGLA (P < 0.0001), and D6D
(P < 0.0001) were positively associated andOA (P = 0.0008), D9D-18 (P = 0.0006), and vitamin D (P < 0.0001) were negatively
associated withWHtR. In longitudinal analysis, baseline linoleic acid (P = 0.018), n–6:n–3 (v-3:v-6) FA ratio (P = 0.029), vitamin
D (P = 0.003), and vitamin E (P < 0.0001) were negatively correlated with WHtR at follow-up only in obese participants.
Conclusions: In T1D youth, plasma FAs and vitamins are associatedwithWHtR and are modified by weight status. These
associations are particularly marked in obese youth. J Nutr 2015;145:579–86.
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Introduction
Children and adolescents with type 1 diabetes (T1D)15 are at
high risk of cardiovascular disease (1, 2). Excess adipose tissue,
especially in the abdominal region, is a well-established risk
factor for the development of cardiovascular disease (3) in the
general population and in individuals with T1D.Waist-to-height
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ratio (WHtR), a marker of central obesity, is the strongest
correlate of total cholesterol and LDL cholesterol in youth with
T1D when compared with waist circumference (WC) and BMI
(4). Because overweight and obesity are common in youth with
T1D (5–7), prevention of excessive abdominal fat accumulation
is of particular concern in youth with T1D in order to decrease
the risks of associated comorbidities, such as cardiovascular and
metabolic disease, in this population.
Several etiologic factors are involved in the accumulation of
adiposity, including inflammation and oxidative stress. Plasma FA
composition reflects both dietary consumption and desaturase
activities (8) and has been associated with metabolic syndrome and
inflammation in youth. Specifically, higher proportions of plasma
n–6 PUFAs are associated with more favorable blood lipid profiles
than those with lower proportions in T1D youth (9) and with lower
concentrations of 2 markers of low-grade inflammation (i.e., IL-6
and CRP) in overweight adolescents without diabetes (10). Further
evidence suggests that deficiencies of certain micronutrients are also
related to greater central obesity. Higher plasma vitamin D
concentrations were associated with lower amounts of abdominal
subcutaneous and visceral adipose tissue in Hispanics and African
Americans (11). As a blood antioxidant, vitamin E was related
to oxidative stress, which starts early in life (12) and can worsen
with age (13). In overweight and obese individuals, higher serum
concentration of vitamin E was also reported to be associated with
lower WC (14). Despite the growing evidence to support these
associations in the general population, data quantifying associations
between plasma FA composition or concentrations of vitaminsD and
E with amounts of central obesity are limited in populations at high
risk of cardiovascular disease, such as individuals with T1D.
As part of the Search for Diabetes in Youth (SEARCH)
Nutrition Ancillary Study (SNAS), we investigated the cross-
sectional and longitudinal association of nutritional plasma
biomarkers with central obesity among youth with T1D. We
hypothesized that plasma FAs, estimated desaturase activities,
and vitamins D and E would be associated withWHtR and these
associations would be modified by weight status. Understanding
these associations in the T1D population can provide insight on
strategies to prevent central obesity in this population already at
risk of cardiovascular disease.
Methods
Population
The SEARCH for Diabetes in Youth Study is an ongoing observational
study with 5 research centers designed to describe the epidemiology of
childhood diabetes. The SNAS was derived from the SEARCH study,
with the aim to examine the associations of nutritional factors with
diabetes-related health outcomes among youth with T1D. The SEARCH
study has ascertained cases of incident T1D in youth younger than 20
since 2002, with follow-up data collected at ;1 and 2 y post–baseline
visit. Both SEARCH and SNAS were reviewed and approved annually by
the appropriate institutional review boards. Written informed consent
and assent were obtained from parents of participants <18 y and from
participants aged $18 y at the time of data collection.
Subject inclusion
These analyses include data from the 2002–2005 incident cohorts of
SEARCH, consisting of participants who were aged 3–20 y when
diagnosed. Cross-sectional analysis included participants who had at
least one available nutritional plasma biomarker (FAs, vitamin D, or
vitamin E) and WHtR from their baseline visit. The sample included
1324 participants, 1104 of whom had at least one measurement of
anthropometry at follow-up and were included in the longitudinal
analysis. (See Supplemental Figure 1 for flowchart of subject inclusion.)
Data collection
Assessment of central obesity. Central obesity is commonly assessed as
WC and WHtR in adults. WHtR, which is calculated as WC divided by
height, is superior toWC alone as a marker of trunk adiposity in youth (15).
Furthermore, WHtR was the strongest indicator for 3 cardiovascular risk
factors (total cholesterol, LDL cholesterol, and diastolic blood pressure) in
youth with T1D in SEARCH (4). Therefore, we used WHtR as the marker
of central obesity in youth with T1D in the present study.
WC was assessed as the circumference just above the right iliac crest
at the midaxillary line according to the NHANES protocol (16). WC and
height were measured twice in centimeters by using a measuring tape and
stadiometer, respectively. If the first 2 measures differed by >1.0 cm for
WC or by >0.5 cm for height, a third measurement was made. WHtR
was calculated by using measured waist (cm) divided by measured height
(cm). Weight was determined in kilograms by an electronic scale to the
nearest 0.1 kg. BMI was calculated for each subject. Overweight was
defined as a BMI$85th and <95th percentile and obesity was defined as
a BMI $95th percentile (7).
Assessment of nutrient biomarkers. Plasma nutrient biomarkers
were measured by using frozen fasting blood samples that were collected
at the time of the SEARCH baseline examination. For FAmeasures, total
lipids were extracted from plasma by the Bligh-Dyer method, and
phospholipids were separated from all other lipids by using one-
dimensional thin-layer chromatography. The proportion of plasma
phospholipid FAs was measured by GC after preparation that included
saponification and transmethylation (17). Data were analyzed with
ChemStation Firmware A.01.09 (Agilent Technologies).
On the basis of a comprehensive review of the literature, we focused
our analyses on select plasma FAs previously related to cardiovascular
risk factors. These included the following: 1) SFAs [palmitic acid (PA;
16:0), stearic acid (SA; 18:0)], 2) MUFAs [palmitoleic acid (POA; 16:1),
oleic acid (OA; 18:1)], 3) n–6 PUFAs [linoleic acid (LA; 18:2), dihomo-
g-linolenic acid (DGLA; 20:3), arachidonic acid (AA; 20:4)], 4) n–3
PUFAs [a-linolenic acid (ALA; 18:3), EPA (20:5), and DHA (22:6)], and
5) the n–6:n–3 FA ratio (10) [(LA + AA + DGLA)/(EPA + DHA + ALA)].
Estimated desaturase activities (18) were calculated as ratios of FAs: D5
desaturase (D5D) activity = AA/DGLA, D6 desaturase (D6D) activity =
DGLA/LA, D9 desaturase 16 (D9D-16) activity = POA/PA, and D9
desaturase 18 (D9D-18) activity was calculated by OA/SA.
The plasma concentration of 25-hydroxyvitamin D [25(OH)D] was
determined by the direct competitive chemiluminescence immunoassay,
which measures 25-hydroxyergocalciferol and 25-hydroxycholecalciferol
(17) (interassay CV: 11.0%). The concentration of vitamin E (a-tocopherol)
in plasma was assayed by HPLC according the method of Cheng et al. (19)
(interassay CV <5%).
Covariates
The following demographic and diabetes-related data were collected at
the baseline visit: sex, self-reported race/ethnicity, age, season (only for
vitamin D), parental education, household income, and clinic site. Data
on diabetes duration and treatment regimen, including type of insulin,
total daily insulin dose (units/kg), frequency of insulin injections, or use
of continuous subcutaneous insulin infusion (insulin pump) were
2 Author disclosures: SWang, JLCrandell, SCCouch, IB King, JMLawrence,DDabelea,
AP Lamichhane, G Kim, RA Bell, S Zhu, and EJ Mayer-Davis, no conflicts of interest.
3 The funding agencies did not contribute to the design and conduct of the SEARCH
Nutrition Ancillary Study nor did they directly participate in management, analysis, or
interpretation of the data.
4 Supplemental Figure 1 and Supplemental Tables 1 and 2 are available from the ‘‘Online
SupportingMaterial’’ link in the online posting of the article and from the same link in the
online table of contents at http://jn.nutrition.org.
*To whom correspondence should be addressed. E-mail: ejmayer-davis@unc.edu.
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16; D9D-18, D9 desaturase 18; LA, linoleic acid; LOD, limit of detection; OA, oleic acid;
PA, palmitic acid; POA, palmitoleic acid; SA, stearic acid; SEARCH,Search forDiabetes in
Youth; SNAS, SEARCH Nutrition Ancillary Study; T1D, type 1 diabetes; WC, waist
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collected from the parent for participants <18 y or from the participants
who were$18 y. Fasting blood samples were obtained under conditions
of metabolic stability (i.e., no episode of diabetic ketoacidosis during the
previous month). Glycated hemoglobin was measured in whole blood
with an automated, nonporous ion-exchange HPLC system (model G-7;
Tosoh Bioscience).
Statistical analysis
Of the 944 participants whose plasma samples were assayed for FAs, 7
were missing POA, 23 were missing ALA, and 7 were missing EPA. No
other FA data were missing. Missing FA percentages may result from an
undetected peak (referred to as ‘‘nondetects’’), which is likely indicative
of a value lower than the detectable limit. Omission of these values can
bias results, and the literature suggests that when the number of
nondetects is small (Environmental Protection Agency guidelines state
<15%), it is appropriate to perform simple imputation, replacing missing
values with small values. The small value chosen is commonly based on
the limit of detection (LOD), such as LOD/2 or LOD/O2 . The units of
the FAs are a ‘‘percentage of total,’’ and the LOD is not well defined in
these units, so we replaced the nondetects with half the lowest observed
value. As a sensitivity analysis, the results were compared with models
with no imputation. No differences were found for POA, ALA, and EPA
in models without and with imputation.
Because of the possibility that associations of plasma nutrient
biomarkers with WHtR might differ according to weight status, the
sample was stratified by BMI category. Descriptive analyses were
conducted to examine the distribution of demographic measures and
baseline nutritional biomarkers across the 3 BMI categories (underweight/
normal weight, overweight, and obese). Chi-square tests and general linear
models were used to compare the 3 groups for categorical data and
continuous data, respectively. Comparison of plasma biomarkers between
the different groups were made with post hoc tests.
Multiple linear regression was used to examine baseline associations
between each nutritional biomarker andWHtR.Models adjusted for the
following potential confounders: 1) demographic variables [age, sex,
race/ethnicity, season (only for vitamin D), highest level of parental
education, clinic site], 2) diabetes-related variables (diabetes duration,
insulin regimen, insulin dose per kilogram, glycated hemoglobin), and 3) BMI
group. Model 1 was unadjusted, model 2 adjusted for demographic and
diabetes-related variables, and model 3 further adjusted for BMI. Because
weight status may modify the association between plasma biomarkers and
central obesity, the interaction between BMI group and each plasma
biomarker was further tested (model 4). A statistically significant interaction
indicated that the relation differed across weight status.
Multiple linear regression was again used to examine the relation
between baseline plasma nutritional biomarkers and WHtR at follow-
up. These models adjusted for the same potential confounders as in the
cross-sectional models, with additional adjustment for baseline WHtR
and time between baseline and follow-up measurements.
Logistic regression was used to predict the odds of incident central
obesity at follow-up from baseline plasma nutrient biomarkers. Central
obesity was defined as measured WC at or above the NHANES-based
age- and sex- specific 90th percentile (20). Incident central obesity was
defined as occurring in participants who were not centrally obese at
baseline but became centrally obese at follow-up. Models adjusted for
the same potential confounders as in the longitudinal multiple regression
models. For the stability of logistic models, some subgroups of
categorical confounders were combined. Model results are described by
using estimated ORs for the incidence of central obesity. All analyses
were performed by using SAS (version 9.2; SAS Institute), with P < 0.05
as the significance level.
Results
Characteristics of participants at baseline. Characteristics of
participants at the time of the baseline visit stratified by weight
status are shown in Table 1. In this sample of youth with T1D
(n = 1324), all ages and both sexes were similarly distributed
across weight status groups. However, overweight and obese
participants were more likely to be non-Hispanic black, to have
parents with lower education, to have lower income, or to take
any combination of insulin excluding long insulin ($3 times/d);
and they were less likely to be using pump therapy. In overweight
and obese participants, the prevalence of central obesity was
25.2% and 78.0%, respectively.
Several of the plasma nutrient biomarkers varied substan-
tially by weight status. Compared with normal-weight partic-
ipants, overweight youth had higher DGLA and lower OA,
D9D-18 activity, and vitamin D; obese youth had higher SA,
DGLA, AA, and D6D activity and lower OA, LA, D9D-18
activity, and vitamin D.
Cross-sectional association between plasma nutrient bio-
markers and WHtR. The unadjusted baseline associations
between nutrient biomarkers and WHtR and the associations
after adjustment for potential confounders and weight status are
shown in Table 2. Across all levels of adjustment, PA, DGLA,
and D6D activity were consistently positively associated with
WHtR; OA, LA, D9D-18 activity, and vitamin D were inversely
associated with WHtR. Other associations did not persist across
all levels of adjustment. Specifically, SA and AA were positively
associated with WHtR in the unadjusted model (model 1). With
additional adjustment for demographic characteristics and
diabetes-related confounders (model 2), EPA was positively
and D5D was negatively associated with WHtR, respectively.
However, these associations were no longer significant after
further adjustment for weight status (model 3).
When the biomarker-WHtR relations were examined
according to weight status (Table 2, model 4), we found
evidence of an interaction between SA, OA, DGLA, D6D
activity, D9D-18 activity, vitamin D, and weight status. The
positive association of WHtR with SA, DGLA, and D6D
activity was only significant in the obese group. In both the
normal-weight and obese group, but not in the overweight
group, vitamin D was negatively related to WHtR. In the
overweight and obese group, OA and D9D-18 activity were
negatively associated with WHtR.
Longitudinal association between baseline plasma nutri-
ent biomarkers and WHtR at follow-up. The relations
between baseline nutritional biomarkers and follow-up WHtR
are shown in Table 3. Higher vitamin D was associated with
lower WHtR at follow-up in models 1 and 3, but no other
biomarkers were significantly related to WHtR at follow-up.
The interaction between the biomarkers and weight status at
follow-up was significant for LA, the n–6:n–3 FA ratio, vitamin
D, and vitamin E. Lower LA, n–6:n–3 FA ratio, vitamin D, and
vitamin E at baseline were found to be associated with higher
WHtR at follow-up only in obese participants.
Odds of central obesity at follow-up. During the follow-up
period, 70 new cases of central obesity among the 923 participants
who were initially free of central obesity (Supplemental Table 1)
were observed. Incident central obesity was more common in
males, in participants aged $15 y at follow-up, and with family
incomes of <$50,000/y. A potential protective effect of SA (model
3) and vitaminD (model 1) against the occurrence of central obesity
was observed (Supplemental Table 2).
Discussion
In the present cross-sectional and longitudinal analyses, several
plasma nutrient biomarkers (PA, SA, OA, LA, DGLA, D6D
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TABLE 1 Baseline characteristics of SEARCH 2002–2005 incident type 1 diabetes cases according to weight status1
All Normal weight Overweight Obese P
n 1324 883 262 177
Age category, n (%) 0.61
2–4 y 66 (5.0) 46 (5.2) 15 (5.7) 5 (2.8)
5–9 y 423 (32.0) 288 (32.6) 75 (28.6) 60 (33.9)
10–14 y 597 (45.2) 389 (44.1) 128 (48.9) 80 (45.2)
$15 y 236 (17.9) 160 (18.1) 44 (16.8) 32 (18.1)
Sex, n (%) 0.25
Female 652 (49.3) 435 (49.3) 138 (52.7) 79 (44.6)
Male 670 (50.7) 448 (50.7) 124 (47.3) 98 (55.4)
Race, n (%) ,0.0001
Non-Hispanic black 126 (9.5) 59 (6.7) 27 (10.3) 40 (22.6)
Non-Hispanic white 1031 (78.0) 733 (83.0) 190 (72.5) 108 (61.0)
Other 165 (12.5) 91 (1.03) 45 (17.2) 29 (16.4)
Parental education, n (%) ,0.0001
Less than high school 61 (4.6) 33 (3.8) 14 (5.4) 14 (8.0)
High school graduate 194 (14.7) 119 (13.5) 40 (15.3) 35 (19.9)
Some college/associates degree 442 (33.6) 274 (31.2) 90 (34.5) 78 (44.3)
Bachelors degree or more 619 (47.0) 453 (51.5) 117 (44.83) 49 (27.8)
Income, n (%) ,0.0001
Dont know/refused 87 (6.6) 69 (7.9) 8 (3.1) 10 (5.7)
,$25,000 160 (12.2) 89 (10.1) 37 (14.1) 34 (19.3)
$25,000–$49,999 299 (22.7) 179 (20.4) 65 (24.8) 55 (31.3)
$50,000–$74,999 261 (19.8) 168 (19.1) 56 (21.4) 37 (21.0)
$$75,000 510 (38.7) 374 (42.6) 96 (36.6) 40 (22.7)
Season of visit, n (%) 0.68
Spring 326 (24.7) 225 (25.5) 64 (24.4) 37 (20.9)
Summer 369 (27.9) 249 (28.2) 70 (26.7) 50 (28.3)
Autumn 288 (21.8) 187 (21.2) 64 (24.4) 37 (20.9)
Winter 339 (25.6) 222 (25.1) 64 (24.4) 53 (29.9)
Insulin regimen, n (%) ,0.01
Pump 121 (9.3) 80 (9.1) 31 (12.1) 10 (5.9)
Long + short/rapid insulin ($3 times/d) 413 (31.7) 290 (33.1) 71 (27.7) 52 (30.4)
Long + any other combination ($2 times/d) 90 (6.9) 74 (8.5) 12 (4.7) 4 (2.3)
Any combination of insulin excluding long ($3 times/d) 188 (14.4) 108 (12.3) 44 (17.2) 36 (21.1)
Any insulin taken 13/d or any insulin combination
excluding long 23/d
490 (37.6) 323 (36.9) 98 (38.3) 69 (40.4)
Other2
Duration of diabetes, mo 10.0 6 6.4 (1324) 10.2 6 6.5 (883) 10.0 6 6.4 (262) 9.1 6 6.1 (177) 0.10
Insulin dose, units/kg 0.6 6 0.4 (1293) 0.6 6 0.4 (868) 0.7 6 0.4 (256) 0.7 6 0.3 (169) 0.04
Outcome
WHtR2 0.48 6 0.06 (1416) 0.45 6 0.03 (883) 0.52 6 0.04 (262) 0.59 6 0.07 (177) ,0.0001
Central obesity, n (%) 231 (16.3) 10 (1.1) 71 (25.5) 150 (77.7) ,0.0001
Nutrient biomarkers
n 944 659 173 111
Plasma FAs, %
PA (16:0) 25.7 6 1.72 25.7 6 1.8 25.7 6 1.6 26.0 6 1.7 0.23
SA (18:0) 15.0 6 1.10 15.0 6 1.1 15.0 6 1.0 15.4 6 1.2*,{ ,0.01
POA (16:1) 0.4 6 0.3 0.4 6 0.4 0.4 6 0.2 0.4 6 0.2 0.66
OA (18:1) 10.0 6 1.2 10.1 6 1.2 9.7 6 1.12* 9.6 6 1.2* ,0.0001
LA (18:2) 25.4 6 2.8 25.5 6 2.8 25.6 6 2.8 24.4 6 2.6*,{ ,0.01
DGLA (20:3) 3.1 6 0.7 3.0 6 0.7 3.2 6 0.7* 3.3 6 0.6* ,0.01
AA (20:4) 13.0 6 1.9 13.0 6 1.9 13.1 6 2.0 13.5 6 2.0* 0.01
ALA (18:3) 0.2 6 0.1 0.2 6 0.1 0.2 6 0.1 0.2 6 0.1 0.27
EPA (20:5) 0.4 6 0.3 0.4 6 0.3 0.4 6 0.2 0.5 6 0.3*,{ 0.06
DHA (22:6) 2.5 6 0.9 2.5 6 0.9 2.5 6 0.7 2.5 6 0.9 0.88
n–6:n–3 14.8 6 4.3 14.9 6 4.2 14.7 6 3.9 14.5 6 5.6 0.58
D5D 4.5 6 1.7 4.5 6 1.9 4.4 6 1.4 4.3 6 1.1 0.38
D6D 0.12 6 0.03 0.12 6 0.03 0.13 6 0.04 0.14 6 0.03*,{ ,0.01
D9D-16 0.01 6 0.01 0.01 6 0.01 0.01 6 0.01 0.01 6 0.01 0.76
D9D-18 0.7 6 0.1 0.7 6 0.1 0.7 6 0.1* 0.6 6 0.1*,{ ,0.0001
(Continued)
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activity, D9D-18 activity, and vitamins D and E) were found to
be associated with WHtR among youth with T1D. Specifically,
higher PA, SA, and DGLA proportions and D6D activity and
lower proportions of OA and LA, and concentrations of
vitamins D and E and D9D-18 activity were associated with
higher WHtR. Several of these associations were modified by
weight status, such that stronger associations were observed in
obese youth than in normal-weight and overweight youth.
The mechanism underlying the link between plasma FAs
and central obesity is not clear. However, there are 2 possible
mechanisms by which plasma FAs may associated with central
obesity. First, certain plasma FAs may directly influence the
accumulation of abdominal adiposity. A diet rich in n–3 PUFAs
has been suggested to have antiobesity effects by modulating
satiety (21) and increasing fat oxidation and energy expendi-
ture (22). Studies in animals showed consistent evidence of an
impact of n–3 PUFA intake on body composition; however,
support in humans is less certain (23). Studies examining the
role of plasma n–3 FAs in the prevention of central obesity are
scarce; however, Micallef et al. (24) reported that greater
concentrations of plasma phospholipid EPA and DHA were
negatively associated with WC in obese adults, although the
reported associations were limited by weak associations and a
lack of controlling for potential confounders. In the present
study, our data showed no evidence of a relation between n–3
PUFAs and WHtR in youth with T1D after accounting for
several major confounders associated with both exposures and
outcomes of interest.
A second mechanism might be that the plasma FAs are
directly related to insulin resistance and inflammation. If this is
the case, the association observed between plasma FAs and
central obesity would be an indirect association and result from
the strong correlation between WHtR and its metabolic conse-
quences. n–6 FAs may be associated with central obesity through
this mechanism. In the current study, a positive association
between DGLA and WHtR and a negative association between
LA and WHtR were identified in obese participants. The
direction of these associations are consistent with results of
TABLE 1 Continued
All Normal weight Overweight Obese P
Plasma vitamins2
25(OH)D, nmol/L 57.4 6 33.4 (1306) 60.6 6 34.7 (873) 52.8 6 30.1* (258) 48.0 6 29.1* (173) ,0.0001
a-Tocopherol, mg/mL 6.2 6 3.0 (1141) 6.3 6 3.1 (765) 6.1 6 2.8 (225) 5.9 6 2.6 (151) 0.21
1 Values are means 6 SDs unless otherwise indicated. There were 2 missing values for BMI. *Different from normal-weight participants, P , 0.05; {Different from overweight
participants, P , 0.05. AA, arachidonic acid; ALA, a-linolenic acid; DGLA, dihomo-g-linolenic acid; D5D, D5 desaturase; D6D, D6 desaturase; D9D-16, D9 desaturase 16; D9D-18,
D9 desaturase 18; LA, linoleic acid; OA, oleic acid; PA, palmitic acid; POA, palmitoleic acid; SA, stearic acid; WHtR, waist-to-height ratio; 25(OH)D, 25-hydroxyvitamin D.
2 n in parentheses.
TABLE 2 Multiple regression analysis examining the unadjusted and adjusted associations between plasma nutrient biomarkers and
WHtR at baseline in youth with type 1 diabetes1
Nutrient
biomarker
b Coefficients for WHtR at baseline
Model 12 Model 23 Model 34
Model 45
P-interactionNormal Overweight Obese
PA (16:0) 0.004 6 0.001** 0.003 6 0.001** 0.002 6 0.001** NS
SA (18:0) 0.004 6 0.002* 0.003 6 0.002 20.0002 6 0.0012 20.002 6 0.001 0.001 6 0.003 0.007 6 0.003* 0.042
POA (16:1) 0.01 6 0.01 0.01 6 0.01 0.007 6 0.004 NS
OA (18:1) 20.009 6 0.002** 20.008 6 0.002** 20.003 6 0.001** 20.002 6 0.001 20.006 6 0.003* 20.01 6 0.01** 0.020
LA (18:2) 20.003 6 0.001** 20.003 6 0.001** 20.001 6 0.001* NS
DGLA (20:3) 0.01 6 0.01** 0.01 6 0.01** 0.005 6 0.002* 0.003 6 0.002 0.001 6 0.004 0.02 6 0.01** ,0.01
AA (20:4) 0.002 6 0.001* 0.002 6 0.001 0.001 6 0.001 NS
ALA (18:3) 20.05 6 0.03 20.05 6 0.03 20.01 6 0.02 NS
EPA (20:5) 0.01 6 0.01 0.02 6 0.01** 0.006 6 0.004 NS
DHA (22:6) 0.002 6 0.002 0.002 6 0.002 0.001 6 0.001 NS
n–6:n–3 FAs 20.0006 6 0.0005 20.0004 6 0.0004 20.0002 6 0.0003 NS
D5D 20.001 6 0.001 20.003 6 0.001* 20.0003 6 0.0008 NS
D6D 0.24 6 0.06** 0.31 6 0.06** 0.11 6 0.04** 0.07 6 0.05 0.05 6 0.08 0.45 6 0.11** ,0.01
D9D-16 0.23 6 0.16 0.25 6 0.15 0.16 6 0.10 NS
D9D-18 20.12 6 0.02** 20.09 6 0.02** 20.03 6 0.01* 20.004 6 0.016 20.06 6 0.03* 20.12 6 0.04** ,0.01
Vitamin D 20.0003 6 0.0001** 20.0002 6 0.0001** 20.0001 6 0.0001** 20.0001 6 0.0001* 20.0001 6 0.0001 20.0005 6 0.0001** ,0.01
Vitamin E 20.0009 6 0.0006 20.0005 6 0.0006 20.0001 6 0.0004 NS
1 Values are b estimates6 SEs. *P, 0.05, **P, 0.01. AA, arachidonic acid; ALA, a-linolenic acid; DGLA, dihomo-g-linolenic acid; D5D, D5 desaturase; D6D, D6 desaturase; D9D-
16, D9 desaturase 16; D9D-18, D9 desaturase 18; LA, linoleic acid; OA, oleic acid; PA, palmitic acid; POA, palmitoleic acid; SA, stearic acid; WHtR, waist-to-height ratio.
2 Model 1 was unadjusted.
3 Model 2 adjusted for demographic variables [age, sex, race/ethnicity, season (only for vitamin D), parental education, household income, clinic site] and diabetes-related variables
(diabetes duration, insulin regimen, insulin dose, and glycated hemoglobin).
4 Model 3 further adjusted for BMI group.
5 Model 4 further included an interaction between biomarker and BMI group.
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previous studies that examined associations of plasma FAs with
markers of inflammation and endothelial activation (25, 26), or
insulin resistance (27, 28), as outcomes. Obesity has been
confirmed as a state of chronic inflammation, which is
related to chronic excessive macronutrient intake (29). In-
creased inflammation-sensitive plasma proteins such as fibrino-
gen and orosomucoid were shown to be predictive of weight
gain (30). Thus, it is probable that n–6 FAs are related to adipose
tissue accumulation through mechanisms involved in modifying
insulin sensitivity or inflammation. However, more clinical trials
are needed to fully explore the causal relations of the associa-
tions between these biomarkers.
Current dietary recommendations advise replacing SFAs,
which is considered ‘‘bad’’ fat, with ‘‘good’’ fat such as MUFAs.
In our study, higher concentrations of SA was related to higher
WHtR in obese participants. However, a potential protective
effect of SAwas observed in participants who were not centrally
obese at baseline. These findings indicate that the association
between SA andWHtR depends on participants obese status. In
addition, higher PA and lower OA were found to be related to
higher WHtR. The administration of OA has been suggested to
inhibit gluconeogenesis and suppress appetite through central
nervous system signaling mechanisms (31). Thus, our results
supported current national nutrition guidelines related to recom-
mended dietary fat type in the T1D population.
Desaturase activities, which regulate the degree of unsatu-
ration of lipids, determine plasma FA profile together with
dietary fat intake (28). Previous studies reported that high
activity of D6D and D9D-16 and low activity of D5D were
related to abdominal adiposity (32, 33), insulin resistance (28,
34), and the development of metabolic syndrome (35). In line
with these observations, we found that higher D6D activity,
which related to higher DGLA, was associated with higher
WHtR at baseline. However, no significant association of
activity of D5D and D9D-16 with WHtR was observed in the
present study. In addition, we found that higher activity of
D9D-18 was associated with lower WHtR at baseline in obese
youth, which may be because more OAwas produced by higher
activity of D9D-18.
Several cross-sectional studies showed that higher concentra-
tions of plasma vitamin D is associated with lower amounts of
abdominal adiposity (11, 36), but no significant longitudinal
associations were identified (11). In the present study, plasma
vitamin D was negatively associated with WHtR at baseline in
normal-weight and obese youth and with WHtR at follow-up in
youth who were obese at baseline. It has been hypothesized that
obesity may be responsible for decreased bioavailability of
cholecalciferol (vitamin D3) from cutaneous and dietary sources
(37). Furthermore, vitamin D3 has been shown to be a powerful
inhibitor of leptin secretion, which regulates adipose deposition
(38). However, our vitamin D assay does not separately quantify
ergocalciferol (vitamin D2) and vitamin D3, so we were unable to
test these hypotheses on vitamin D3 alone. As with vitamin D,
higher baseline plasma vitamin E was associated with lower
WHtR longitudinally in obese youth in our study. This is in
accordance with previous data suggesting that vitamin E is
negatively related to central obesity in both serum (39) and
adipose tissue (40). Furthermore, all longitudinal associations
existed only in participants who were obese, suggesting that
weight status may influence associations between plasma
biomarkers and obesity. The mechanism underlying these asso-
ciations might be that suboptimal vitamin E concentrations may
contribute to inadequate antioxidant defenses, which further
contributes to accumulation of body fat (12).
TABLE 3 Multiple regression analysis examining the unadjusted and adjusted associations between plasma nutrient biomarkers and
WHtR at follow-up in youth with type 1 diabetes1
Nutrient biomarker
b Coefficients for WHtR at follow-up
Model 12 Model 23 Model 34
Model 45
P- interactionNormal Overweight Obese
PA (16:0) 0.001 6 0.001 0.0006 6 0.0008 20.0001 6 0.0007 NS
SA (18:0) 20.001 6 0.001 20.0005 6 0.0013 20.001 6 0.001 NS
POA (16:1) 20.005 6 0.004 20.003 6 0.006 20.004 6 0.005 NS
OA (18:1) 20.001 6 0.001 20.0005 6 0.0012 0.0001 6 0.0010 NS
LA (18:2) 0.0008 6 0.0005 20.0001 6 0.0005 0.0004 6 0.0004 0.0009 6 0.0005 0.001 6 0.001 20.003 6 0.001* 0.012
DGLA (20:3) 20.003 6 0.002 20.003 6 0.002 20.003 6 0.002 NS
AA (20:4) 20.0008 6 0.0007 0.0005 6 0.0007 20.0001 6 0.0006 NS
ALA (18:3) 0.003 6 0.020 20.02 6 0.02 20.02 6 0.02 NS
EPA (20:5) 0.002 6 0.005 0.002 6 0.005 20.0007 6 0.0045 NS
DHA (22:6) 0.0001 6 0.0015 20.0003 6 0.0016 20.0005 6 0.0013 NS
n–6:n–3 FAs 20.0002 6 0.0003 20.0001 6 0.0003 0.0001 6 0.0003 0.0004 6 0.0003 0.0008 6 0.0007 20.001 6 0.001* 0.021
D5D 0.001 6 0.001 0.002 6 0.001 0.001 6 0.001 NS
D6D 20.06 6 0.04 20.04 6 0.04 20.05 6 0.03 NS
D9D-16 20.1 6 0.1 20.1 6 0.2 20.1 6 0.1 NS
D9D-18 20.004 6 0.014 20.0001 6 0.015 0.01 6 0.01 NS
Vitamin D 20.0001 6 0.0001** 20.0001 6 0.0001 20.0001 6 0.0001* 20.0001 6 0.0001 20.0001 6 0.0001 20.0003 6 0.0001** 0.029
Vitamin E 0.0001 6 0.0004 20.0004 6 0.0004 20.0007 6 0.0004 20.0001 6 0.0004 20.0001 6 0.0010 20.005 6 0.001** ,0.01
1 Values are b estimates6 SEs. *P, 0.05, **P, 0.01. AA, arachidonic acid; ALA, a-linolenic acid; DGLA, dihomo-g-linolenic acid; D5D, D5 desaturase; D6D, D6 desaturase; D9D-
16, D9 desaturase 16; D9D-18, D9 desaturase 18; LA, linoleic acid; OA, oleic acid; PA, palmitic acid; POA, palmitoleic acid; SA, stearic acid; WHtR, waist-to-height ratio.
2 Model 1 adjusted for baseline WHtR and time between the baseline and the follow-up examinations.
3 Model 2 further adjusted for demographic variables [age at follow-up, sex, race/ethnicity, season (only for vitamin D), parental education, household income, clinical site] and
diabetes-related variables (diabetes duration, insulin regimen, insulin dose, and glycated hemoglobin at follow-up).
4 Model 3 further adjusted for BMI group at follow-up.
5 Model 4 further included an interaction between biomarker and BMI group.
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A limitation of our study is that we used WHtR as a marker
of central obesity in children and adolescents instead of DXA or
MRI, which are more accurate in assessing visceral adipose
tissue. Future studies would benefit from the use of DXA orMRI
to assess fat distribution or body composition. However, WHtR,
as an established predictor of many cardiovascular risk factors,
is also a rapid and effective indicator of central obesity in
epidemiologic studies and is an easily measured clinical measure
of central obesity (41). We also acknowledge the small sample
sizes of the obese group and incident cases of central obesity,
which may have resulted in limited power to detect significant
interactions in the multiple regression analyses or significant
ORs in the logistic regression.
The strengths of our study are noteworthy. First, the SNAS is
a multicenter prospective study with a larger sample size than
previous cross-sectional studies (24, 42). Second, our study is
novel in that it explores the association between individual
plasma FAs and central obesity in youth with T1D. Most
previous studies in this area focused on FA classes among
healthy individuals or in those with type 2 diabetes, so existing
findings obtained from other populations are needed to be
confirmed in a T1D population. Third, blood FA biomarkers of
dietary intake, which can serve as independent measures of diet
not subject to the measurement errors of dietary surveys, have
the potential to be used more quantitatively (43). An additional
strength of this study is our large sample size, which allowed us
to control for desired potential confounders and to include an
analysis of effect modification.
In conclusion, several plasma nutrient biomarkers were
associated with WHtR at baseline and follow-up in youth with
T1D, independent of BMI. The favorable plasma nutrient
profile associated with optimal fat distribution included higher
proportions of OA, LA, and vitamins D and E concentrations
and D9D-18 activity and lower proportions of PA, SA, and
DGLA and D6D activity. Of these, some associations are
particularly marked in obese youth. These findings raise the
possibility that a diet of high nutritional quality, such as a
Mediterranean-type diet, would likely reduce central adiposity
by increasing amounts of beneficial plasma biomarkers in
youth with T1D. However, this hypothesis needs to be
confirmed in future studies. In addition, the exact mechanisms
of these associations are unclear; more feeding studies and
dietary interventions are needed to explore the mechanisms,
particularly related to the potential enhancement of effects
among obese individuals.
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